How I manage venous thromboembolism risk in hospitalized medical patients

Blood

Volumn 120, Issue 8, 2012, Pages 1562-1569

  Dobromirski, Mark ^a   Cohen, Alexander T ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; DALTEPARIN; ENOXAPARIN; ESTROGEN; FONDAPARINUX; HEPARIN; RIVAROXABAN;

ACUTE HEART INFARCTION; AGE DISTRIBUTION; ANTICOAGULANT THERAPY; AUTOIMMUNE DISEASE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL PRACTICE; COMPRESSION GARMENT; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; EMERGENCY HEALTH SERVICE; ENTERITIS; GENETIC DISORDER; HOSPITALIZATION; HUMAN; IMMOBILIZATION; INFECTION; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; MEDICAL HISTORY; NEOPLASM; OBESITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; RHEUMATIC DISEASE; RISK ASSESSMENT; RISK MANAGEMENT; THROMBOPHILIA; THROMBOSIS PREVENTION; TREATMENT DURATION; VARICOSIS; VENOUS STASIS; VENOUS THROMBOEMBOLISM;

EID: 84865432941     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-378901     Document Type: Review

References (98)

1. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394. (Pubitemid 351173321)
2. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed). Chest. 2008;133(6 Suppl):381S-453S. (Pubitemid 351894916)
3. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ. 1991;302(6778):709-711.
4. Kakkar N, Vasishta RK. Pulmonary embolism in medical patients: an autopsy-based study. Clin Appl Thromb Hemost. 2008;14(2):159-167. (Pubitemid 351364021)
5. Heriot GS, Pitman AG, Gonzales M, McKelvie P. The four horsemen: clinicopathological correlation in 407 hospital autopsies. Intern Med J. 2010;40(9):626-632.
6. Lloyd NS, Douketis JD, Moinuddin I, Lim W, Crowther MA. Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. J Thromb Haemost. 2008;6(3):405-414. (Pubitemid 351280106)
7. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Ed). Chest. 2012;141(2 Suppl):195S-226S.
8. Cohen AT, Edmondson RA, Phillips MJ, Ward VP, Kakkar VV. The changing pattern of venous thromboembolic disease. Haemostasis. 1996;26(2):65-71. (Pubitemid 26139622)
9. Alikhan R, Peters F, Wilmott R, Cohen AT. Fatal pulmonary embolism in hospitalised patients: a necropsy review. J Clin Pathol. 2004;57(12):1254-1257. (Pubitemid 39611508)
10. Faraj AA. Implementing National Institute of Clinical Excellence guidelines for venous thromboembolism prophylaxis. Am J Med Sci. 20112;343(3):131-135.
11. Amin AN, Lin J, Yang G, Stemkowski S. Are there any differences in the clinical and economic outcomes between US cancer patients receiving appropriate or inappropriate venous thromboembolism prophylaxis? J Oncol Pract. 2009;5(4):159-164.
12. Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005;94(4):750-759. (Pubitemid 41489233)
13. Spyropoulos AC, Anderson FA Jr, Fitzgerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011;140(3):706-714.
14. Alonso Ortiz del Rio C, Medrano Ortega F, Romero Alonso A, Villar Conde E, Calderon Sandubete E, Marin Leon I. Prevention of thromboembolic venous disease in medical patients (PRETEMED). 2003. http://www.guidecentral.com/ guidelines-1/prevention-of-thromboembolicvenous-disease-in-medical-patients- pretemed. Accessed February 29, 2012.
15. Manly DA, Boles J, Mackman N. Role of tissue factor in venous thrombosis. Annu Rev Physiol. 2011;73:515-525.
16. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938-949.
17. Cimmino G, D'Amico C, Vaccaro V, D'Anna M, Golino P. The missing link between atherosclerosis, inflammation and thrombosis: is it tissue factor? Expert Rev Cardiovasc Ther. 2011;9(4):517-523.
18. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164(9):963-968. (Pubitemid 38581515)
19. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD: the Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med. 2000;161(4):1109-1114.
20. Beemath A, Stein PD, Skaf E, Al Sibae MR, Alesh I. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol. 2006;98(6):793-795. (Pubitemid 44301013)
21. Lawson CA, Yan SD, Yan SF, et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest. 1997;99(7):1729-1738. (Pubitemid 27163825)
22. Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet. 2010;375(9715):657-663.
23. Matta F, Singala R, Yaekoub AY, Najjar R, Stein PD. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost. 2009;101(1):134-138.
24. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis: a systematic review of clinical studies. Thromb Haemost. 2005;94(2):362-365. (Pubitemid 41122491)
25. Kröger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2006;17(2):297-303. (Pubitemid 43160121)
26. Luxembourg B, Schmitt J, Humpich M, et al. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: a focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP). Thromb Haemost. 2009;102(4):668-675.
27. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood. 1995;86(10):3685-3691.
28. Zöller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012;379(9812):244-249.
29. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol. 2008;143(3):321-335.
30. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. N Engl J Med. 2003;348(15):1435-1441. (Pubitemid 36407172)
31. Emerson PA, Marks P. Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking. Br Med J. 1977;1(6052):18-20. (Pubitemid 8016477)
32. Simmons AV, Sheppard MA, Cox AF. Deep venous thrombosis after myocardial infarction: predisposing factors. Br Heart J. 1973;35(6):623-625.
33. Kelly J, Rudd A, Lewis RR, Coshall C, Moody A, Hunt BJ. Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. Stroke. 2004;35(10):2320-2325. (Pubitemid 39311256)
34. Sherman DG, Albers GW, Bladin C, et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet. 2007;369(9570):1347-1355. (Pubitemid 46621092)
35. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158(6):585-593. (Pubitemid 28144815)
36. Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost. 2010;8(10):2105-2112.
37. Lowe GD, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol. 1997;97(4):775-784. (Pubitemid 27321375)
38. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebocontrolled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-879. (Pubitemid 39096017)
39. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793-800. (Pubitemid 29420474)
40. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325-329.
41. Prandoni P, Lensing AW, Cogo A, et al. The longterm clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1-7.
42. Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ. 2011;342:d813.
43. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis: Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med. 2001;345(3):165-169. (Pubitemid 32662124)
44. Kearon C. Long-term anticoagulation for venous thromboembolism: duration of treatment and management of warfarin therapy. Clin Chest Med. 2010;31(4):719-730.
45. Murin S, Romano PS, White RH. Comparison of outcomes after hospitalization for deep venous thrombosis or pulmonary embolism. Thromb Haemost. 2002;88(3):407-414. (Pubitemid 35021597)
46. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.
47. Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009;169(6):610-615.
48. Noboa S, Le Gal G, Lacut K, et al. Family history as a risk factor for venous thromboembolism. Thromb Res. 2008;122(5):624-629.
49. Roberts LN, Patel RK, Arya R. Venous thromboembolism and ethnicity. Br J Haematol. 2009;146(4):369-383.
50. Hill J, Treasure T. Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance. BMJ. 2010;340:c95.
51. Alikhan R, Cohen AT, Combe S, et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis. 2003;14(4):341-346. (Pubitemid 36688187)
52. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153(1):8-18.
53. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160(22):3415-3420.
54. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):338S-400S. (Pubitemid 39302602)
55. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809-815. (Pubitemid 30165241)
56. Agnelli G, George DJ, Kakkar AK, et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366(7):601-609.
57. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3(1):27-34. (Pubitemid 34121143)
58. Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008;6(9):1517-1524.
59. Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005;104(12):2822-2829. (Pubitemid 41798294)
60. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.
61. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484-3488. (Pubitemid 35303914)
62. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-5505. (Pubitemid 350232226)
63. Rocha AT, de Vasconcellos AG, da Luz Neto ER, Araujo DM, Alves ES, Lopes AA. Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery. Obes Surg. 2006;16(12):1645-1655. (Pubitemid 46032819)
64. Darvall KA, Sam RC, Silverman SH, Bradbury AW, Adam DJ. Obesity and thrombosis. Eur J Vasc Endovasc Surg. 2007;33(2):223-233. (Pubitemid 46076268)
65. Rao GH, Thethi I, Fareed J. Vascular disease: obesity and excess weight as modulators of risk. Expert Rev Cardiovasc Ther. 2011;9(4):525-534.
66. Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: "the study of men born in 1913." Arch Intern Med. 1999;159(16):1886-1890. (Pubitemid 29424708)
67. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697-706.
68. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22(2):201-210. (Pubitemid 34127028)
69. Cano A, Van Baal WM. The mechanisms of thrombotic risk induced by hormone replacement therapy. Maturitas. 2001;40(1):17-38. (Pubitemid 33048840)
70. Mahmoodi BK, Gansevoort RT, Veeger NJ, et al. Microalbuminuria and risk of venous thromboembolism. JAMA. 2009;301(17):1790-1797.
71. Wattanakit K, Cushman M, Stehman-Breen C, Heckbert SR, Folsom AR. Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol. 2008;19(1):135-140.
72. Wattanakit K, Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med. 2009;15(5):408-412.
73. Kusminsky RE. Complications of central venous catheterization. J Am Coll Surg. 2007;204(4):681-696. (Pubitemid 46437369)
74. Fan J, Li X, Cheng Y, Yao C, Zhong N. Measurement of D-dimer as aid in risk evaluation of VTE in elderly patients hospitalized for acute illness: a prospective, multicenter study in China. Clin Invest Med. 2011;34(2):E96-E104.
75. Desjardins L, Bara L, Boutitie F, et al. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med. 2004;128(5):519-526. (Pubitemid 38579588)
76. Cohen AT, Spiro TE, Burton P, et al. The MAGELLAN Study: an analysis of outcomes utilizing D-dimer. https://ash.confex.com/ash/2011/webprogram/ Paper42824.html. Accessed February 29, 2012.
77. Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004;2(12):2156-2161. (Pubitemid 40185776)
78. Barbar S, Noventa F, Rossetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost. 2010;8(11):2450-2457.
79. Woller SC, Stevens SM, Jones JP, et al. Derivation and validation of a simple model to identify venous thromboembolism risk in medical patients. Am J Med. 2011;124(10):947-954.
80. Dennis M, Sandercock PA, Reid J, et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet. 2009;373(9679):1958-1965.
81. Turpie AG, Leizorovicz A. Prevention of venous thromboembolism in medically ill patients: a clinical update. Postgrad Med J. 2006;82(974):806-809. (Pubitemid 46101928)
82. Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2011;155(9):625-632.
83. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost. 2000;83(1):14-19. (Pubitemid 30045469)
84. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146(4):278-288. (Pubitemid 351650614)
85. Cohen AT, Spiro TE, Buller HR, et al. Extendedduration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011;31(4):407-416.
86. Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167-2177.
87. Cohen AT, Buller HR, Mebazaa A, et al. Rivaroxaban compared with enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. Presented at the annual scientific session of the American College of Cardiology, New Orleans, LA, April 5, 2011. Presentation slides available online at http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/@scon/ documents/downloadable/ucm-425442.pdf.
88. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694. (Pubitemid 41647882)
89. National Institute for Health and Clinical Excellence. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. http://www.nice.org.uk/guidance/CG92. Accessed February 29, 2012.
90. Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139(1):69-79.
91. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101(8):2955-2959. (Pubitemid 36857979)
92. Prandoni P, Siragusa S, Girolami B, Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood. 2005;106(9):3049-3054. (Pubitemid 41565898)
93. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed). Chest. 2008;133(6 Suppl):340S-380S. (Pubitemid 351892970)
94. Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9(12):2389-2396.
95. Khanna R, Vittinghoff E, Maselli J, Auerbach A. Unintended consequences of a standard admission order set on venous thromboembolism prophylaxis and patient outcomes. J Gen Intern Med. 2012;27(3):318-324.
96. Bagot C, Gohil S, Perrott R, Barsam S, Patel RK, Arya R. The use of an exclusion-based riskassessment model for venous thrombosis improves uptake of appropriate thromboprophylaxis in hospitalized medical patients. QJM. 2010;103(8):597-605.
97. Arnone D, Hansen L, Davies G. Pulmonary embolism and severe depression. Am J Psychiatry. 2002;159(5):873-874.
98. McCall WV, Mann SC, Shelp FE, Caroff SN. Fatal pulmonary embolism in the catatonic syndrome: two case reports and a literature review. J Clin Psychiatry. 1995;56(1):21-25.